Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Search results for

There are 22,003 results that match your search.22,003 results
  • Print
    Why biosimilars are being held back in the US
    No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where this leaves the industry
    Managing IP Correspondent, December 06 2013
  • lakshmikumaran.jpg
    India: No compulsory licence without reasonable efforts
    In October 2013, the Controller General of Patents rejected M/s BDR Pharmaceuticals International's application seeking a compulsory licence for Bristol Myers Squibb's patent covering the active pharmaceutical ingredient dasatinib, which is used to treat patients with chronic myeloid leukemia (CML). The application was rejected at a prima facie level due to the applicant's failure to make reasonable efforts to seek a voluntary licence.
    Managing IP Correspondent, December 06 2013
  • four.jpg
    Moves: Honigman Miller and Brooks Kushman hire in the US
    Honigman Miller Schwartz and Cohn has grown its IP litigation group with three new partners. Jamal Edwards joins the firm's Detroit office. He is a former partner of Kirkland & Ellis, a former regional counsel for the IBM Corporation in Chicago and a former executive with Equifax.
    Managing IP Correspondent, December 06 2013
  • charbucks.jpg
    Trade mark news
    The international coffee shop chain Starbucks has failed to stop a US coffee roasting company from selling a product called Charbucks. Starbucks sued the New Hampshire-based Wolfe's Borough Coffee, which trades as Black Bear Micro Roastery, more than a decade ago. In November the Second US Circuit Court of Appeals in New York backed a lower court that had declined to ban the defendant from selling Charbucks coffee.
    Managing IP Correspondent, December 06 2013
  • Editorial: The patent party won’t last forever
    One of the aims of this column is to be provocative, so here goes: there are good reasons to think that the continual and impressive growth in patent filing reported in the latest IP5 report will not continue, and that before long the number of applications will decline.
    Managing IP Correspondent, December 06 2013
  • dvorak.jpg
    A "good" NPE speaks out
    Universities such as Caltech are often held up as examples of good NPEs in discussions about intellectual property. What sorts of challenges do they face?
    December 06 2013
  • Australian senators call for TPP transparency
    Members of the upper house in Australia’s parliament have called for the government to publish the final text of the trans-Pacific free trade deal before it is signed off by the cabinet
    December 06 2013
  • Innovation Act passed intact by US House of Representatives
    The Innovation Act was passed by the House of Representatives in a 325-91 vote yesterday, despite some heated opposition. It survived amendments that would have removed provisions moving to a loser-pays system and diluted the covered stay provisions
    December 06 2013
  • kappos-david-cravath.jpg
    Goodlatte bill if enacted would quickly need to be fixed: Kappos
    Former USPTO director David Kappos believes patent reform is being "rushed" in the House, with the Goodlatte bill up for vote this week, and has identified a number of issues with the legislation.
    December 05 2013
  • IP5 filings
    The patent party won’t last forever
    We are seeing a patent Bubble; we should not necessarily expect a Bust. But we might be wise to prepare for a Correction
    December 05 2013
Previous
1
...
1061
1062
1063
1064
1065
...
2200
Next